Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Humacyte, Inc.NASDAQ: HUMA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $23.32M fell 50.1% year over year, ahead of the -61.2% change in trailing-twelve-month financing cash flow. Sequentially, it fell 59.2% from the prior quarter.
Context
- Financing cash flow amounted to 3017.0% of revenue in FY2025.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -50.1% holds above the trailing-twelve-month pace of -61.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 61.49M USD
- Year-over-year change
- -46.2%
- 4-year CAGR
- -30.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 61.49M | -46.2% |
| FY2024 | 2024-12-31 | 114.18M | +2433.5% |
| FY2023 | 2023-12-31 | 4.51M | +411.7% |
| FY2022 | 2022-12-31 | (1.45M) | -100.5% |
| FY2021 | 2021-12-31 | 266.98M | — |
Financing Cash Flow vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 financing cash flow of $38.07M is the 4th largest of the 11 companies compared; the peer median is $969K.
- Its year-over-year change of -61.2% is the 9th highest of 11, against a peer median of +143.5%.
- Financing cash flow amounts to 1888.3% of revenue for HUMA, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $212.95M | +1074.3% | +2184.5% | — | |
| LTM Mar 2026 | $51.55M | +779.8% | +38.7% | — | |
| LTM Mar 2026 | $50.66M | -51.5% | -16.6% | 179.5% | |
| LTM Mar 2026 | $38.07M | -61.2% | — | 1888.3% | |
| LTM Mar 2026 | $25.14M | +10830.9% | — | — | |
| LTM Mar 2026 | $4.07M | +227.6% | -9.7% | 11.1% | |
| LTM Mar 2026 | $2.36M | +59.4% | — | 1.1% | |
| LTM Mar 2026 | $1.8M | -109.8% | — | 4.0% | |
| LTM Mar 2026 | $1.3M | +41.9% | -27.5% | — | |
| LTM Mar 2026 | $637K | -99.4% | +22.8% | 11.1% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $275K | +1118.5% | — | — |
| Peer median (excluding HUMA) | $969K | +143.5% | +6.5% | 11.1% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 5.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 6.18M | 6.83M | 6.14M | 9.75M |
| Change in Working Capital | (557K) | 1.03M | 6.57M | 311K | (23.4M) |
| Accounts Receivables | (63K) | 145K | 31K | 0 | (261K) |
| Inventory | 0 | 0 | 0 | 0 | (21.83M) |
| Accounts Payables | (197K) | (509K) | 4.81M | (1.96M) | 973K |
| Other Working Capital | (297K) | 1.39M | 1.73M | 2.27M | (2.28M) |
| Other Non-Cash Items | (72.54M) | (74.59M) | 16.35M | 36.94M | (55.9M) |
| Operating Cash Flow | (81.19M) | (71.13M) | (73.31M) | (98.12M) | (105.04M) |
| Capital Expenditures | (220K) | (1.05M) | (2.28M) | (1.57M) | (884K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (8M) | (10.11M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 16M | 2.11M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (8.22M) | 4.85M | (173K) | (1.57M) | (884K) |
| Debt Repayment | 27.93M | (1.98M) | 5.7M | (2.58M) | 36.39M |
| Common Stock Issued | 598K | 535K | 566K | 45.93M | 113.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 239.05M | 535K | (1.76M) | 27.71M | (88.34M) |
| Financing Cash Flow | 266.98M | (1.45M) | 4.51M | 114.18M | 61.49M |
| Effect of Forex Changes | 0 | 0 | (209K) | 0 | 0 |
| Net Change in Cash | 177.57M | (67.73M) | (69.18M) | 14.49M | (44.44M) |
| Free Cash Flow | (81.41M) | (72.18M) | (75.59M) | (99.69M) | (105.93M) |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.